Table 1:
Demographic and clinical characteristics of patients who performed a RT-PCR test during the study period and were included in the cohort
| N | 33,993 | |
| positive for SARS-CoV-2, N (%) | 46.75 (17.41) | |
| age | mean (SD) | 16,630 (48.9 %) |
| 18–39 | 13,310 (39.2 %) | |
| 40–59 | 11,498 (33.8 %) | |
| ≥ 60 | 9,185 (27.0 %) | |
| sex | Female | 16,630 (48.9 %) |
| Male | 17,363 (51.1 %) | |
| socio-economic status (1–20) | mean (SD) | 9.98 (3.74) |
| missing (%) | 3,154 (10.23 %) | |
| Ethnic group | Arab | 5,143 (15.1 %) |
| General | 25,826 (76.0 %) | |
| Jewish Ultra-orthodox | 3,024 (8.9 %) | |
| days elapsed | since 2nd dose of the vaccine, median [IQR] | 146 [121–167] |
| ≥146 days since vaccination, N (%) | 17,211 (50.6 %) | |
| between 1st and 2nd dose of vaccine, median [IQR] | 21 [21–21] | |
| comorbidities | diabetes mellitus, N (%) | 4,351 (12.8 %) |
| hypertension, N (%) | 8,095 (23.8 %) | |
| asthma, N (%) | 2,996 (8.8 %) | |
| COPD, N (%) | 1,618 (4.8 %) | |
| ischemic heart disease, N (%) | 2,038 (6.0 %) | |
| solid tumor, N (%) | 2,085 (6.1 %) | |
| chronic kidney disease, N (%) | 750 (2.2 %) | |